7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register.**

The following transactions were granted early termination of the waiting period provided by law and the premerger notification rules. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period:

Transaction	Waiting period terminated effective
(1) 85-1109—Malrite Communications Group, Inc.'s (Milton Maltz, UPE), proposed acquisition of assets of radio stations KLAC-AM and KZLA-FM, L.A. Radio Station (Capital Communications, Inc., UPE).	Oct. 1, 1985.
(2) 85-1110—Malrite Communications Group, Inc.'s (Milton Maltz, UPE), proposed acquisition of assets of radio station KSSR (American Broadcasting Companies, Inc., UPE).	Do.
(3) 85-1114—Park Communications, Inc.'s (Roy H. Park, UPE), proposed acquisition of assets of radio stations WPAT-AM and FM (Capital City Communications, Inc., UPE).	Do.
(4) 85-1115—The Edward W. Scripps Trust's proposed acquisition of assets of television station WXYZ (American Broadcasting Companies, Inc., UPE).	Do.
(5) 85-1116—The Edward W. Scripps Trust's proposed acquisition of voting securities of Tampa Bay Television, Inc. (Capital Cities Communications, Inc., UPE).	Do.
(6) 85-1117—Pocklington Financial Corp.'s proposed acquisition of voting securities of Kretschmar Brands, Inc. (Tim Loveless, UPE).	Do.
(7) 85-1118—Pocklington Financial Corp.'s proposed acquisition of voting securities of Kretschmar Brands, Inc. (Susan Loveless, UPE).	Do.
(8) 85-1144—Centuri, Inc.'s proposed acquisition of voting securities of Poloron Products, Inc.	Do.
(9) 85-1153—The Washington Post Company's (Katharine Graham, UPE), proposed acquisition of voting securities of eight subsidiaries of Cable Television Division (Capital Cities Communications, Inc., UPE).	Do.
(10) 85-1162—Eastman Kodak Company's proposed acquisition of assets of Bell & Howell Company.	Do.
(11) 85-1168—W. Galen Weston's proposed acquisition of voting securities of Betsy Ross Foods, Inc.	Do.
(12) 85-1178—Den Norske Creditbank's proposed acquisition of voting securities of Nordic American Banking Corporation.	Do.
(13) 85-1189—Emhart Corporation's proposed acquisition of assets of True Temper Corp., Jackson & Cyclone Division of Wilkenson Match, Inc. and True Temper Sports Company (Allegheny International, Inc., UPE).	Do.
(14) 85-1123—Cook Inlet Communications, L.P.'s proposed acquisition of assets of Capital Cities Communications, Inc.	Oct. 2, 1985.
(15) 85-1125—Emerson Electric Co.'s proposed acquisition of voting securities of J.H. Fenner (Holdings) PLC.	Do.
(16) 85-1184—Viacom International, Inc.'s proposed acquisition of voting securities of WCI/WASEC, Inc. and Amex/WASEC, Inc. (Warner Amex Cable Holding Company, UPE).	Do.
(17) 85-1172—The Coca-Cola Company's proposed acquisition of voting securities of Nutri-Foods International, Inc.	Oct. 3, 1985.
(18) 85-1198—Baltimore Bancorp's proposed acquisition of assets of Municipal Savings & Loan Association, Inc.	Do.
(19) 85-1173—The Signal Companies, Inc.'s proposed acquisition of voting securities of Frankel Manufacturing Company.	Oct. 4, 1985.
(20) 85-1195—Elsevier-NDU N.V.'s proposed acquisition of assets of the University Microfilms International Division (Xerox Corporation, UPE).	Do.
(21) 85-1221—M.I.M. Holdings Limited's proposed acquisition of voting securities of ASARCO Incorporated.	Do.
(22) 85-1224—Merrill Lynch & Co., Inc.'s proposed acquisition of assets or voting securities of Consumer Foods and Pigments (SCM Corporation, UPE).	Do.
(23) 85-1183—BTL Inc.'s proposed acquisition of assets of Clark Oil and Refining Corporation, Clark Chemical Corporation (Apex Oil Company, UPE).	Oct. 7, 1985.
(24) 86-0035—Numerica Financial Corporation's proposed acquisition of voting securities of Home Bank, FSB.	Do.
(25) 85-1207—Allied Products Corporation's proposed acquisition of assets of White Farm Equipment Co. (Stratton J. Geogoulis, UPE).	Oct. 8, 1985.
(26) 85-1145—NL Industries, Inc.'s proposed acquisition of voting securities of Edgewater Corporation (The Hillman Company, UPE).	Oct. 9, 1985.
(27) 85-1151—Allegheny International, Inc.'s proposed acquisition of voting securities of Edgewater Corporation (Henry L. Hillman, UPE).	Do.
(28) 85-1204—Victor N. Goulet's proposed acquisition of voting securities and assets of Electronic Realty Associates, Inc., Relocation Realty Service Corp. (Control Data Corporation, UPE).	Oct. 10, 1985.
(29) 85-1216—Mitsubishi Corporation's proposed acquisition of voting securities of Kux Manufacturing Company.	Do.
(30) 85-1223—W.R. Grace & Co.'s proposed acquisition of assets of Casa Gallardo Inc. and Darryl's (General Mills, Inc., UPE).	Do.
(31) 85-1142—Continental Telecom, Inc.'s proposed acquisition of voting securities of Fairchild Space Communications, Inc. and American Satellite Corporation (Fairchild Industries, Inc., UPE).	Oct. 11, 1985.
(32) 85-1192—W.R. Grace & Co.'s proposed acquisition of voting securities of Hungry Tiger Inc.	Oct. 15, 1985.

FOR FURTHER INFORMATION CONTACT:
Sandra M. Peay, Legal Technician, Premerger Notification Office, Bureau of Competition, Room 301, Federal Trade Commission, Washington, DC 20580, (202) 523-3894.

By direction of the Commission.

Emily H. Rock,

Secretary.

[FR Doc. 85-25734 Filed 10-28-85; 8:45 am]

BILLING CODE 6750-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control

Project Grants for Preventive Health Services-Sexually Transmitted Diseases Professional Education; Availability of Funds for Fiscal Year 1986

Introduction

The Centers for Disease Control (CDC) announces the availability of funds for Fiscal Year 1986 for a Project Grant for Sexually Transmitted Diseases (STD) Professional Education. This grant will be for the Western and Southwestern area of the United States, consisting of Arizona, California, and Nevada, and will be funded under the Sexually Transmitted Diseases Research, Demonstrations, and Public and Professional Education Grant Program. The Catalog of Federal Domestic Assistance Number is 13.978. This program is authorized by section 318(b) of the Public Health Service Act, as amended (42 U.S.C. 247c(b)). Regulations governing Grants for Sexually Transmitted Diseases Research, Demonstrations, and Public and Professional Education (formerly Veneral Disease Research, Demonstrations, and Public Information and Education) ar codified in Part 51b at Subparts A and F of Title 42, Code of Federal Regulations.

Purpose

The objectives of the program of grants under section 318(b) of the Public Health Service Act are to develop, improve, and evaluate methods for the prevention and control of STD through demonstrations and applied research; to develop, improve, apply, and evaluate methods and strategies for public information and education about STD; and to support particularly deserving STD public and professional education programs. The professional education objective is the purpose of this announcement. It is designed to meet the 1990 Objective of the Nation which states that 95 percent of health providers seeing suspected cases of STD will be capable of diagnosing and treating all diseases and syndromes that fall within that definiton. This will be accomplished primarily by training health department STD clinicians, but also by updating the STD knowledge of private sector practitioners, by educating physicians-in-training to whatever extent their curricula permit, and by demonstatratinng quality standards for the care of patients with

STD. The achievement of the 1990 objective clinical capability and the other objectivies to reduce STD cases and complications are mutually dependent and are national in scope. Therefore, it is necessary to assure that this training initiative is coordinated effectively with the basic control components of the local STD program. It must also be coordinated with CDC to assure that the total training environment represents a national model, that training is consisent with guidelines and is uniform nationwide, and that all course offerings can be broadly publicized by CDC. The objective of this specific grant offering is to establish an STD Prevention/Training (P/T) Center to serve the clinical and disease intervention specialist training needs primarily of STD clinicians from the Western and Southwestern parts of the United States.

Eligible Applicants

Eligible applicants are the official State or local health agencies in Arizona, California, and Nevada. Awards will be limited to applications who meet the following minimum requirements:

1. Plan to locate the P/T Center in a health department clinic that:

a. Is dedicated to the diagnosis and treatment of STD patients,

b. Serves an average of at least 300 patients per 40 weekly service hours, and

c. Serves patients of sufficient demographic variety morbidity to support and stimulate the learing process.

2. Have at least one university school of medicine in the vicinity and provide evidence of support, experience, and a firm interest in participating from such a local institution.

3. Provide assurance that a full schedule of training activities will begin within 180 days of the date of grant award.

4. Provided evidence of their capability of adhering to the CDC document entitled "Quality Assurance Guidelines for STD Clinics, 1982" (Clinic QAG) in providing diagnostic and treatment services, and to applicable portions of the CDC document entitled "STD Prevention/Training Center Curriculum Guidelines and Performance Standards for STD Clinical Training" (P/T Center Guidelines) in the training of health personnel prior to beginning any training activities.

5. Provide evidence of their willingness to adhere to CDC curriculum in the presentation of STD intervention outreach training courses.

Availability of Funds

Approximately $230,000 will be available for Fiscal Year 1986 to fund one new grant award. It is expected that the initial grant will begin on or about April 1, 1986, and will be funded for 12 months in a 2- to 5-year project period. Continuation awards within the project period will be made on the basis of satisfactory progress in meeting project objectives, compliance with the P/T Center Guidelines and the Clinic QAG, or future updates thereof, and on the availability of funds. The funding estimate outlined above may vary and is subject to change.

Use of Funds

Funds may be used to support a direct assistance (i.e., "in lieu of cash") position in the dual roles of P/T Center coordinator/instructor of STD intervention outreach courses. If such a request is made, CDC will make an individual available for assignment at the earliest possible date following the award. CDC will assist in the training and preparation of the person or persons designated to carry out these responsibilities. Funds will not be awarded for the purchase or lease of land or buildings or for the construction of a facility. Except where another agency normally houses and public STD clinic, the P/T Center should be located in the health department facility. Funds will not be awarded to renovate existing space, without adequate justification, including appropriate detailed diagrams, reliable estimates of cost, and a realistic projection of the time required for completion.

Reporting requirements

Financial status reports are required no later than 90 days after the end of each budget period. Final financial status and progress reports are required 90 days after the end of a project period.

Guidelines for Application Narrative

Applications must include a narrative which, in addition to the minimum requirements for an eligible application as stated above, details the following: (1) Evidence that the State/local health department is willing to work toward meeting STD 1990 Objectives for the Nation; (2) evidence that the training component of this project will function in concert with the operating STD clinic and STD intervention outreach components of the local control program; (3) long- and short-term objetives of the proposal training which address the applicant's expected role over the project period in meeting the STD 1990 Objectives for the Nation and which establish the applicant's anticipated training accomplishments for the initial budget period; (4) the activities and methods which will be employed to accomplish the objectives, (including relationships, responsibilities, and procedures that ensure the P/T Center functions according to the Clinic QAG and the P/T Center Guidelines); (5) a description of the existing medical school-health department liaison activities needed to develop and implement clinical training; (6) an evaluation plan which will help determine if the methods are effective and the objectives are being achieved; (7) a budget with justification; and (8) any other information which will support the request for assistance.

Review and Evaluation Critiera

Grant applications will be reviewed and evaluated based on the evidence submitted which specifically describes (with documentation and attachments) the applicant's ability to meet the following criteria:

1. The applicant conveys a satisfactory commitment from the State/local health department administration toward meeting STD 1990 Objectives for the Nation, and specifically, that objective related to the preparation of STD clinicians to adequately diagnose and treat STD, and to conduct such noninvasive STD research that may be feasible and which will not conflict with other program priorities.

2. The applicant satisfactorily describes how the P/T Center corresponds to the needs, plans, and objectives of the State/local STD program; how the P/T Center activities will be effectively coordinated with the basic control components of the local STD program; and how both will be coordinated with CDC to assure that that the total training environment repesents a national model.

3. The applicant's expected role over the project period in meeting STD 1990 Objectives for the Nation and anticipated training accomplishments for the initial budget period are satisfactorily addressed in the long- and short-term objectives.

4. The applicant adequately assures that STD diagnostic and treatment services will be provided principally in accordance with the Clinic QAG, in particular:

a. There will be adequate space and staff to accommodate patient volume.

b. There will be at least 5 days of full clinical services provided (a minimum of 35 registration hours during a minimum of 40 patient service hours, including at least one evening or Saturday session

each week) with no interim daily shutdowns.

c. Clinic management responsibility will be assigned to one person with clinical and/or administrative skills and experience.

d. Diagnosis and treatment will be provided for most STD and their syndromes (e.g., syphilis, gonorrhea, chlamydial infections and associated syndromes, pelvic inflammatory disease, herpes, trichomoniasis, human papilloma virus, scabies, etc.).

e. A nurse clinician or nurse clinician and physician assistant model of care will be used with a physician available on-site for consultation.

f. An integrated flow will be used which minimuzes the number of patient stops and the amount of patient waiting time.

g. Patients will be seen, regardless of sex, by the next available clinician.

h. Confidentiality will be observed during both patient registration and patient care service delivery.

i. A standardized (e.g., "checkoff"), fully auditable, STD medical record will be employed.

j. There will be an on-site laboratory facility which offers a range of immediately available (stat) tests for commonly seen STD.

k. There will be quality assurance procedures through which clinical care is audited systematically and the proficiency of stat laboratory activities are assessed periodically through smear/culture and serologic test correlations.

l. CDC diagnostic guidelines will be used (e.g., bimanual examinations for women, complete genital examinations for males).

m. The policies and procedures of the STD clinic will harmoniously complement the activities of the disease intervention outreach component of the program.

n. CDC recommended treatment schedules will be used.

5. The applicant adequately assures that the development and operation of the clinical component of the proposed P/T Center will be according to the P/T Center Guidelines, in particular:

a. There will be adequate training space for both clinical and STD intervention outreach courses and assurances that it will be available for all scheduled courses.

b. Classroom space will be adequately furnished and equipped.

c. The positions of P/T Center coordinator and STD intervention outreach training instructor will be identified or be provided for either through a proposal to create and fill these positions or through a request for a position in which both responsibilities will be carried out by a person CDC would provide through direct assistance.

d. A clerical resource will be identified and available on-site to assist the P/T Center Training Coordinator or will be provided for through a proposal to create and fill such a position.

e. The curricula will be developed according to P/T Center Guidelines.

f. The clinic and stat laboratory practicum will be structured such that participants are provided an opportunity to demonstrate their clinical skills under the supervision of P/T Center personnel by performing STD examinations on patients and practicing STD stat laboratory procedures.

g. There will be evaluation of student and medical school teaching faculty performance.

h. A minimum of 400 hours of instruction will be provided annually to P/T Center students which consists of at least six "core" courses (two of which are "Comprehensive"), and two different types of course offerings, as described by the P/T Center Guidelines.

i. The medical school personnel will play a dominant role in classroom training.

6. There is a commitment in principle from a local university medical school to participate with the applicant in the establishment of a P/T Center which addresses the following:

a. Part of the time of a liaison/coordinating physician (preferably a physician in the second or third year of a fellowship) with the expense of medical school faculty instructional services being covered by the most cost-effective mechanism possible.

b. The medical school's participation in the development of curriculum that is governed by the P/T Center Guidelines.

c. A minimum of 400 hours of instruction that will be provided annually which consists of at least six "core" courses (two of which are "Comprehensive"), and two different types of course offerings, as described in the P/T Center Guidelines.

d. Faculty assistance from the medical school in clinic practicum through the use of residents or fellows.

e. The medical school's reinforcement of the provisions of the Clinic QAG during curriculum development, instruction, and precepting clinic practicum.

f. The medical school's arrangement for medical students, accompanied by faculty preceptors, to rotate through the center for training and clinic practicum.

7. The applicant provides a satisfactory evaluation plan which will help determine if the methods are effective and the objectives are being achieved.

8. The budget request is clearly explained, adequately justified, reasonable, cost-effective, and consistent with the intended use of grant funds.

9. The site of the proposed P/T Center is sufficiently near to major highways that accessibility by car is a reasonable option.

10. The location of the proposed P/T Center is convenient to restaurants and reasonable hotel/motel accommodations and accessible through a local ground transportation system from an airport.

Site visits may also be made in connection with the review of applications.

Application Information

The original and two copies of the application must be submitted to Leo A. Sanders, Chief, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control, 255 East Paces Ferry Road, NE., Room 321, Atlanta, Georgia 30305, on January 2, 1986.

A. Deadline: Applications shall be considered as meeting the deadline if they are either:

1. Received at the above address on or before the deadline date; or

2. Sent on or before the deadline date and received in time for submission to the independent review group. (Applicants must request a legibly dated U.S. Postal Service postmark or obtain a legibly dated receipt from a commercial carrier or U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.)

B. Late Applications: Applications which do not meet the criteria in A. 1. or 2. above are considered late applications. Late applications will not be considered in the current competition and will be returned to the applicant.

C. Review Requirements: Applications are subject to review as governed by Executive Order 12372, Intergovernmental Review of Federal Programs, and regulations (42 CFR Part 122, as amended, and Part 123) implementing the National Health Planning and Resources Development Act of 1974.

D. Where to Obtain Additional Information: Information on application procedures, copies of application forms, and other material may be obtained from Betty Feeley, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control, 255 East Paces Ferry Road, NE., Room 321, Atlanta,

Georgia 30305, or by calling (404) 262–6575 or FTS 236–6575. Technical assistance may be obtained from Albert N. Brasile, Division of Sexually Transmitted Diseases, Center for Prevention Services, Centers for Disease Control, Atlanta, Georgia, 30333, telephone (404) 329–2558 or FTS 236–2558.

Dated: October 21, 1985.

William E. Muldoon,

Director, Office of Program Support, Centers for Disease Control.

[FR Doc. 85–25704 Filed 10–28–85; 8:45 am]

BILLING CODE 4160–18–M

Food and Drug Administration

[Docket No. 78P–0148 et al.]

Availability of Approved Variances for Laser Light Shows

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that variances from the performance standard for laser products have been approved by FDA's Center for Devices and Radiological Health (CDRH) for six organizations that manufacture and produce laser light shows, light show projectors, or both. The projectors provide a laser light display to produce a variety of special lighting effects. The principal use of these products is to provide entertainment to general audiences.

DATES: The effective dates and termination dates of the variances are listed in the table below under **"SUPPLEMENTARY INFORMATION."**

ADDRESS: The applications and all correspondence on the applications have been placed on display in the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm. 4–62, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Tracy Summers, Center for Devices and Radiological Health (HFZ–84), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 310–443–4874.

SUPPLEMENTARY INFORMATION: Under § 1010.4 (21 CFR 1010.4) of the regulations governing establishment of performance standards under section 358 of the Radiation Control for Health and Safety Act of 1968 (42 U.S.C 263f), CDRH has granted each of the six organizations listed in the table below a variance from § 1040.11(c) (21 CFR 1040.11(c)) of the performance standard for laser products.

Each variance permits the listed manufacturer to introduce into commerce a demonstration laser product assembled and produced by the manufacturer, which is its particular variety of laser light show, laser light show projector, or both. Each laser product involves levels of accessible laser radiation in excess of Class II levels but not exceeding those required to perform the intended function of the product.

CDRH has determined that suitable means of radiation safety and protection are provided by constraints on the physical and optical design, by warnings in the user manual and on the products, and by procedures for personnel who will operate the products. Therefore, on the effective dates specified in the table below, FDA approved and requested variances by a letter to each manufacturer from the Deputy Director of CDRH.

So that each product may show evidence of the variance approved for the manufacturer of the product, each product shall bear on the certification label required by § 1010.2(a) (21 CFR 1010.2(a)) a variance number, which is the FDA docket number, and the effective date of the variance as specified in the table below.

Docket number	Organization granted the variance	Demonstration laser product	Effective date/ Termination date
78P–0148 (amendment)	Laser Media, Inc., 2046 Armacost Avenue, Los Angeles, California 90025.	Laser Media, Inc., LM and EMS laser projection systems, the LMT and Fiberray fiber-optically coupled projector heads, and laser shows assembled and produced by Laser Media, Inc. which incorporate any of these projection devices and/or the Stingray and Chromaray Model Series projectors.	Aug. 14, 1985–May 9, 1986.
83V–0228 (extension)	Laser Light Production's The Space Center, Tombaugh Planetarium, P.O. Box 533, Alamogordo, New Mexico 88310.	Space Center's Tombaugh Planetarium laser light show incorporating the Laser Systems Development Corporation Laser Projector Model C–3(a).	Aug. 5, 1985–Aug. 5, 1987.
85V–0204	Laser Dynamics, Inc., P.O. Box 4156, Spokane, Washington 99202.	Laser ligh shows produced and assembled by Laser Dynamics, Inc. with a Class IV argon and helium-neon laser projector manufactured and certified by Laser Fantasy Productions, Inc. (formerly Coherent Innovations, Inc.).	Aug. 5, 1985–Aug. 5, 1986
85V–0230	Halloran Equities Corp., 7999 Route 130, Pensauken, New Jersey 08110.	Bratz Discotheque laser light shows assembled and produced by Halloran Equities Corp. incorporating Halloran Equities Class IV argon laser projector, Model 1.	Aug. 1, 1985–Aug. 1, 1987.
85V–0273	MHS, Inc., 8000 Madison Pike, Madison, Alabama 35758.	Laserpoint, Ltd. Aries, Scorpion, and 1000D Series of Class IV argon and/or krypton laser projection systems and for laser light shows produced by MHS, Inc./dba Meteor Light and Sound Company.	July 25, 1985–July 25, 1987.
85V–0324	Laser Spectacles, Inc., 9114 Bintliff, P.O. Box 740188, Houston, Texas 77274.	Class IV krypton Model 1001 LUXME Laser Projector and laser light shows produced and assembled by Laser Spectacles, Inc. containing this projector.	Aug. 2, 1985–Aug. 1, 1987.

In accordance with § 1010.4, the applications and all correspondence on the applications have been placed on public display under the designated docket number in the Dockets Management Branch (address above) and may be seen in that office between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Public Health Service Act as amended by the Radiation Control for Health and Safety Act of 1968 (sec. 358, 82 Stat. 1177–1179 (42 U.S.C. 26f)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.86).

Dated: October 21, 1985.

John C. Villforth,

Director, Center for Devices and Radiological Health.

[FR Doc. 85–25673 Filed 10–28–85; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 85F–0469]

General Electric Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that General Electric Co. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of polycarbonate resins

produced by the condensation of 4,4'-isopropylindenediphenol, carbonyl chloride, terephthaloyl chloride, and isophthaloyl chloride for use in contact with food.

FOR FURTHER INFORMATION CONTACT: Vir Anand, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 5B3898) has been filed by General Electric Co., Pittsfield, MA 01201, proposing that § 177.1580 *Polycarbonate resins* (21 CFR 177.1580) be amended to provide for the safe use of polycarbonate resins produced by the condensation of 4,4'-isopropylidenediphenol, carbonyl chloride, terephthaloyl chloride, and isophthaloyl chloride for use in contact with food.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c), as published in the **Federal Register** of April 26, 1985 (50 FR 16636).

Dated: October 17, 1985.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 85-25672 Filed 10-28-85; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 84P-0264]

Grated Cheeses Deviating From Identity Standard; Extension of Temporary Permit for Market Testing

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the extension of a temporary permit issued to Sargento Cheese Co., Inc., to market test grated cheeses containing powdered cellulose as an anticaking agent. This extension will allow the permit holder to continue experimental market testing of the product while the agency takes action on a petition to amend the standard of identity for grated cheeses which the permit holder submitted jointly with other sponsors.

DATE: The new expiration date of the permit will be either the effective date of a final rule for any proposal to amend the standard of identity for grated cheeses which may result from the petition, or 30 days after termination of such rulemaking.

FOR FURTHER INFORMATION CONTACT: Johnnie G. Nichols, Center for Food Safety and Applied Nutrition (HFF-215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-485-0101.

SUPPLEMENTARY INFORMATION: A temporary permit was issued under the provisions of 21 CFR 130.17 to Sargento Cheese Co., Inc., Plymouth, WI 53073, to market test grated cheeses containing powdered cellulose as an anticaking agent. The permit was issued in order to facilitate market testing of foods that deviate from the requirements of the standards of identity promulgated under section 401 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 341). Notice of issuance of the temporary permit to Sargento Cheese Co., Inc., was published in the **Federal Register** of September 4, 1984 (49 FR 34965).

Sargento Cheese Co., Inc., has requested that the temporary permit be extended so the market test period can continue while agency action on a petition to amend the grated cheeses standard proceeds. Sargento Cheese Co., Inc., in accoradance with 21 CFR 130.17(i), submitted a petition to amend 21 CFR 133.146 at the same time the application for extension was submitted. FDA is inviting interested persons to participate in the market test under the conditions that apply to Sargento Cheese Co., Inc., including the labeling requirements and the amounts of test product to be distributed except that the designated area of distribution shall not apply.

Any interested person who wishes to participate in the extended market test must notify, in writing, the Deputy Director, Division of Food Technology (HFF-211), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 200 C St. SW., Washington, DC 20204. The notification must include the amount of test product to be distributed, the area of distribution, and the labeling that will be used for the test product (i.e., a label for each size, each variety, and each brand of product to be test marketed).

Therefore, under the provisions of 21 CFR 130.17(i), FDA is extending the expiration date of the permit such that the permit expires either on the effective date of a final rule for any proposal to amend the standard of identity for grated cheeses which may result from the petition, or 30 days after termination of such rulemaking. All other conditions and terms of this permit remain the same.

Dated: October 21, 1985.

Sanford A. Miller,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 85-25669 Filed 10-28-85; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 83P-0429]

Grated Cheeses Deviating From Identity Standard; Extension of Temporary Permit for Market Testing

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the extension of a temporary permit issued to Schreiber Foods, Inc., to market test grated cheeses containing powdered cellulose as an anticaking agent. This extension will allow the permit holder to continue experimental market testing of the product while the agency takes action on a petition to amend the standard of identity for grated cheeses which the permit holder submitted jointly with other sponsors.

DATE: The new expiration date of the permit will be either the effective date of a final rule for any proposal to amend the standard of identity for grated cheeses which may result from the petition, or 30 days after termination of such rulemaking.

FOR FURTHER INFORMATION CONTACT: Johnnie G. Nichols, Center for Food Safety and Applied Nutrition (HFF-215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-485-0101.

SUPPLEMENTARY INFORMATION: A temporary permit was issued under the provisions of 21 CFR 130.17 to Schreiber Foods, Inc., Green Bay, WI 54305-5610, to market test grated cheeses containing powdered cellulose as an anticaking agent. The permit was issued in order to facilitate market testing of foods that deviate from the requirements of the standards of identity promulgated under section 401 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 341). Notice of issuance of the temporary permit to Schreiber Foods, Inc., was published in the **Federal Register** of January 26, 1984 (49 FR 3271).

Schreiber Foods, Inc., has requested that the temporary permit be extended so the market test period can continue while agency action on a petition to amend the grated cheeses standard